Christopher Mach

**Title: The Innovations of Christopher Mach in the Field of Melanin Concentrating Hormone Receptor Ligands**

Introduction

Christopher Mach, an accomplished inventor based in Fairfield, CT, has made significant contributions to the understanding and potential treatment of various metabolic and sexual disorders through his innovative work in pharmacology. With a focus on melanin concentrating hormone (MCH) receptor ligands, Mach's research holds promise for developing therapies that could impact both human and animal health.

Latest Patents

Christopher Mach holds a notable patent titled "Melanin Concentrating Hormone Receptor Ligands: Substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole Analogues." This innovation involves creating ligands capable of modulating MCH receptor activity. These ligands can significantly affect MCH binding to MCH receptors, both in vivo and in vitro. This breakthrough has potential applications in treating a variety of metabolic, feeding, and sexual disorders for humans, domesticated companion animals, and livestock. Additionally, methodologies for using these ligands in receptor localization studies have been developed, further broadening their scope of application.

Career Highlights

Throughout his career, Christopher Mach has worked with Neurogen Corporation, a company focused on advancing therapeutics for serious diseases. His work has involved not only inventing but also transforming scientific discoveries into practical pharmaceutical compositions. This endeavor demonstrates his commitment to improving health outcomes through innovation.

Collaborations

In his quest for innovation, Christopher Mach has collaborated with talented colleagues such as Robert W. DeSimone and John M. Peterson. These partnerships have enhanced research efforts, fostering a collaborative environment that thrives on diverse expertise and shared goals in the biotechnology and pharmaceutical sectors.

Conclusion

Christopher Mach's inventive contributions, particularly in the realm of MCH receptor ligands, showcase the vital role of innovation in medicine and pharmacology. His patented work at Neurogen Corporation exemplifies how targeted research can lead to significant advancements in treating metabolic and sexual disorders, highlighting the importance of continued exploration in this crucial area of health science.